GLP-1 Drugs and Tirzepatide Linked to 29% Lower Relative Risk of Kidney Failure Than Finerenone, but No Clear Absolute Difference, in TriNetX Study
Researchers at Hebrew University and Hadassah Medical Center reported in Diabetes, Obesity and Metabolism on October 7, 2026 a records study of 4,554 matched adults with type 2 diabetes and stage 3 or 4 chronic kidney disease who started a GLP-1 drug or tirzepatide, or finerenone, a non-steroidal kidney drug. Kidney failure or dialysis occurred in 4.8% versus 6.0% within 2.5 years (hazard ratio 0.71), but the absolute risk difference of 1.14 percentage points was not statistically clear. Albuminuria, a key kidney measure, was missing for most people, so the authors warned of residual confounding.